Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
... periodically during therapy.
Hepatic
impairment
Metabolism of Tasigna is mainly ... hepatic impairment. Patients with moderate renal
impairment (CrCL = 20-39 mL/min) should receive a 50% ... are not recommended in patients with mild renal
impairment (CrCL = 40-59 mL/min). For patients with moderate ...
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
... hepatic impairment. Patients with moderate renal
impairment (CrCL = 20-39 mL/min) should receive a 50% ... are not recommended in patients with mild renal
impairment (CrCL = 40-59 mL/min). For patients with moderate renal
impairment doses greater than 400 mg are not recommended. ...
Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
... or
inattentive symptoms that cause
impairment were present before age 7 years;
that some
impairment from the symptoms is present in two or more ... there is clear evidence of
clinically significant
impairment in social, academic, or occupational
functioning ...
Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets
... related to
Alzheimer's called mild cognitive
impairment (MCI). The researchers saw
improvement on various ... for Psychiatric Research.
Rates of Cognitive
impairment Higher Than Anticipated
As the field of ... the
earliest point in the disease. Mild Cognitive
impairment (MCI) is the term
used to describe the ...
Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
... the American Spinal Injury
Association, or ASIA,
impairment Scale. Analysis of the data by dose ... were measured using the ASIA
impairment Scale, or AIS. Evaluations
were completed at 0, ... cervical SCI (classified as grade A on
the ASIA
impairment Scale) were enrolled in the trial.
The ...
Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment
... on April 16.
Individuals with mild cognitive
impairment can function reasonably well
in everyday ... Most (but not all)
patients with mild cognitive
impairment develop a progressive decline in
their thinking ... to 89
years old. Of those, 128 had mild cognitive
impairment and 740 were
cognitively normal. The team ...
Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
... ongoing Phase 2a trial for
MEM 3454 in cognitive
impairment associated with schizophrenia and report
top-line ... a Phase 2a trial of MEM 3454 in cognitive
impairment associated with schizophrenia (CIAS). The ... CNS
disorders, many of which exhibit significant
impairment of memory and other
cognitive functions, ...
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
... the American Spinal
Injury Association, or ASIA,
impairment Scale. The ASIA
impairment Scale is
used to score subjects within five categories from A to E, with A being
complete
impairment with no sensory or motor function below the site ...
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
... efficacy, comparable safety and less
impairment of quality of life on treatment -
- Final results ... of
treatment - with comparable safety and less
impairment of health-related
quality of life on treatment. ... safety and the potential for less
impairment of quality of life
and daily activity," said ...
Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
... associated with fewer missed work days and less
impairment of quality of life on treatment than ... reported fewer missed days of
work and less
impairment of health-related quality of life on ... treatment
group. All Albuferon groups showed less
impairment of health-related
quality of life based on SF-36 ...
Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference
...
Neurologists Surveyed on Diagnosing and Treating Mild Cognitive
impairment (MCI)
Scientists at ICAD 2009 reported on how clinicians view and treat mild cognitive
impairment (MCI), a research category used to define the state between normal aging ...
Neuroscience Researcher Has Positive Message for International Alzheimer's Awareness Week, July 6 - 12: 'Even Though World Economy is Declining, Alzheimer's Research is Advancing'
... that causes those neurons to stop functioning and brings about cognitive
impairment and symptoms associated with Alzheimer's," says Underwood.
"Knowing ... stop producing these proteins at a faster rate so their cognitive
impairment occurs with greater velocity."
Underwood says he is confident that a ...
New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
... component:
BENICAR HCT is not recommended in patients with severe renal
impairment and is contraindicated in patients with anuria or hypersensitivity to ... other adverse reactions that have occurred in adults.
Hepatic
impairment
Thiazides should be used with caution in patients with impaired hepatic ...
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
... include a charge of $1.1 million for the restructuring and related asset
impairment resulting from the Company's strategic restructuring plan to discontinue ... administrative 3,084 4,183
Restructuring & asset
impairment 1,056 -
----- ...
Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
... depression, bipolar disorder, Alzheimer's disease, mild cognitive
impairment and other neuropsychiatric and neurodegenerative disorders where there is ... (e.g. major depression, bipolar disorder, PTSD, mild cognitive
impairment and schizophrenia) and neurological diseases (e.g. Parkinson's and ...
Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
... R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cognitive
impairment associated with schizophrenia (CIAS). The Company has randomized 212 ... treatment of debilitating CNS disorders, many of which exhibit significant
impairment of memory and other cognitive functions, including Alzheimer's disease ...
Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease
... cognitive
changes. Currently available tests for detecting cognitive
impairment are
either insensitive to the specific changes that occur in Parkinson's, ... then follow over time to determine the
ability of MoCA to detect cognitive
impairment in PD. Validation of the
MoCA will provide a critical research tool needed ...
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
... onset of some hyperactive,
impulsive or inattentive symptoms that caused
impairment appears before age
7 years; that some
impairment from the symptoms is present in two or more
settings (eg, at school and ...
Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's
... candidate for
predicting Alzheimer's in people with mild cognitive
impairment (MCI). MCI
is a transition stage between the cognitive changes of normal ... (BACE1) functional
candidate biomarkers in subjects with mild cognitive
impairment and
Alzheimer's disease." (Funders: Science Foundation Ireland, ...
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
... falling asleep. These improvements were achieved without
any next day
impairment of cognition or coordination.
"APD125 is a potential next generation ... events and no emerging safety findings as compared to placebo. No
next day
impairment of cognition or coordination was observed and there was
no evidence of ...
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
... improvements were seen in neurologic examination using the
Neurological
impairment Score - Lower Limbs (NIS-LL) and quantitative
sensory testing (QST) which ... the visual analog scale for pain intensity
(VASPI), a modified Neuropathy
impairment Score - Lower Limbs (NIS-LL)
scoring system as well as total neuropathy ...
CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
... are living longer, studies suggest that therapies such as CNIs can
cause
impairment of kidney function, damage to the blood vessels, and
filtering capacity of ... for PML, including treatment with immunosuppressant therapies and
impairment of immune function. In immunosuppressed patients, physicians should ...
Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
... are living
longer, studies suggest that therapies such as CNIs can cause
impairment of
kidney function, damage to the blood vessels, and filtering capacity of ... for PML, including treatment with immunosuppressant therapies and
impairment of immune function. In immunosuppressed patients, physicians should ...
Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
... top-line results for its Phase 2a trial of R3487/MEM 3454 in cognitive
impairment associated with schizophrenia (CIAS) in the fourth quarter -- ... treatment of debilitating CNS
disorders, many of which exhibit significant
impairment of memory and other
cognitive functions, including Alzheimer's disease and ...
Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
... the onset of which appears before age 7 years;
that some
impairment from the symptoms is present in two or more settings
(e.g., at school and ... continue for at least six
months; and that there is clinically significant
impairment in social,
academic or occupational functioning and the symptoms cannot be ...
New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
... the onset of which appears before age 7 years;
that some
impairment from the symptoms is present in two or more settings
(e.g., at school and ... continue for at least six
months; and that there is clinically significant
impairment in social,
academic or occupational functioning and the symptoms cannot be ...
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
... the onset of which appears before age 7 years;
that some
impairment from the symptoms is present in two or more settings
(e.g., at school and ... continue for at least six
months; and that there is clinically significant
impairment in social,
academic or occupational functioning and the symptoms cannot be ...
Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
... of patients treated with Cethrin demonstrated an improvement in
their
impairment level on the American Spinal Injury Association scale that
was ... injuries who were treated with
Cethrin showed improvement using the same
impairment scale that was almost
700% greater than the full patient group treated ...
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454
... payment upon the completion of the ongoing Phase 2a study
in cognitive
impairment associated with schizophrenia (CIAS). In addition,
Memory Pharmaceuticals ... treatment of debilitating CNS
disorders, many of which exhibit significant
impairment of memory and other
cognitive functions, including Alzheimer's disease and ...
Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
... the onset of which appears before age 7 years;
that some
impairment from the symptoms is present in two or more settings
(e.g., at school and ... continue for at least six
months; and that there is clinically significant
impairment in social,
academic or occupational functioning and the symptoms cannot be ...
Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008
... There was improvement
using the American Spinal Injury Association (ASIA)
impairment scale in
combined thoracic and cervical patients approximately four times ... injuries who were treated with CETHRIN showed improvement using the
same
impairment scale that was almost seven times greater than the full
patient group ...
Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
... from a study of diabetic mice
with the Haptoglobin 2-2 genotype that show
impairment in the clearance of
the Haptoglobin (Hp)-Hemoglobin (Hb) complex may ... The study also
demonstrated that vitamin E supplementation prevented the
impairment of
reverse cholesterol transport in diabetic mice with the Hp2-2 ...
ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans
... structurally similar, thus
depressing nervous system activity. Cognitive
impairment due to central
cholinergic dysfunction, or scopolamine administration, is ... EEG changes have been
considered as possible biomarkers for AD as the
impairment acetylcholine's
activity is one of the landmarks of this disease.
The ...
OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
... keratitis (AK), a serious eye infection that can
result in vision
impairment or blindness. AK, which in its ocular form most
commonly infects contact ... and include a combination of prescription
eye medications. Severe vision
impairment or loss of the eye may occur,
even if the condition is diagnosed early and ...
FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
... range from urticaria to anaphylaxis);
patients with end-stage renal
impairment at less than 10 mL/min creatinine
clearance or patients undergoing ... be avoided because additional reductions in
alertness and additional
impairment of CNS performance may occur.
In clinical trials, the most common ...
Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
... trial with LX6171, an oral drug candidate
for the treatment of cognitive
impairment associated with disorders such as
Alzheimer's disease, schizophrenia, and ... and cognitive effects in elderly subjects with
age-associated memory
impairment (AAMI).
"AAMI is an emerging area of clinical research and offers an ...
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
... the onset of which appears before age 7 years;
that some
impairment from the symptoms is present in two or more settings
(e.g., at school and ... continue for at least six
months; and that there is clinically significant
impairment in social,
academic or occupational functioning and the symptoms cannot be ...
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
... improvements as measured by the BASFI, a
1 to 10 scale (1 representing no
impairment and 10 representing severe
impairment), which measures physical function and
impairment due to the
disease and subsequent improvements as a result of treatment. ...
Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
... the onset of which
appears before age 7 years; that some
impairment from the symptoms is
present in two or more settings (e.g., at school and ... continue for at least six months; and that there is clinically
significant
impairment in social, academic or occupational functioning and
the symptoms cannot be ...
Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
... the onset of which appears before age 7 years;
that some
impairment from the symptoms is present in two or more settings
(e.g., at school and ... continue for at least six
months; and that there is clinically significant
impairment in social,
academic or occupational functioning and the symptoms cannot be ...